About
One Six 8 Ventures is a venture capital firm partnering with exceptional entrepreneurs to build transformative early-stage MedTech companies. Our core mission is to back innovations that fundamentally improve patient outcomes while creating substantial market value.
Our investment focus is clear: early-stage Medical Technology. We maintain a disciplined approach, targeting specific sub-sectors where innovation can drive significant clinical and market impact.
Built over nearly two decades, our team offers a distinct advantage: direct experience as founders, operators, and executives within VC-backed MedTech and life sciences. This allows us to conduct deep, multi-faceted due diligence and actively partner with founders post-investment. We provide hands-on strategic and operational guidance, leveraging our experience to help companies navigate growth, manage risk effectively, preserve capital, and achieve market leadership.
Our investment focus is clear: early-stage Medical Technology. We maintain a disciplined approach, targeting specific sub-sectors where innovation can drive significant clinical and market impact.
Built over nearly two decades, our team offers a distinct advantage: direct experience as founders, operators, and executives within VC-backed MedTech and life sciences. This allows us to conduct deep, multi-faceted due diligence and actively partner with founders post-investment. We provide hands-on strategic and operational guidance, leveraging our experience to help companies navigate growth, manage risk effectively, preserve capital, and achieve market leadership.
THE TEAM
The One Six 8 Ventures team comprises seasoned operators and executives with deep roots in scaling VC-backed life sciences companies over nearly two decades. We act as hands-on partners to our portfolio founders, providing strategic guidance and support grounded in extensive industry experience. Learn more about our team below:
Judyanna Yu, CPA, CAManaging Partner
CFO, Providence Therapeutics CFO & COO, Restem Biotech CFO, Biochem Group VP Corporate Finance, Cerecin Health business entrepreneur Previous: Manning Elliott LLP, KPMG, Auditor General of Alberta Board, BioAlberta Board, Pharmsky Research |
Charles Stacey, MD, MBAPartner
President & CEO, Cerecin Inventages Venture Capital ($1.5B AUM) Orthopaedics and trauma surgeon in London Medtech entrepreneur Board of Governors, Accreditation Council for Medical Affairs |
Ankang Li, PhD, JD, CFAAdvisor
CFO, CSO and Executive Director, Brii Biosciences CEO, TSB Therapeutics CFO, Terns Pharmaceutical Executive Director, Healthcare Investment Banking, Goldman Sachs, BD Director, Merck, Associate at Davis Polk, Ropes & Gray |
Xi Qiao, MScPrincipal
Head of BD Commercial Evaluation, Fosun Pharma, Consultant at Boston Consulting Group, Pricing and Market Access Manager, AstraZeneca, Health & TMT Senior Consultant, Ernst & Young |
ADVISORS
Alden Aumann, CPA, CA• Managing Partner, Manning Elliott LLP
|
Neeraj Gupta• Serial entrepreneur, angel investor, board member for startups/ NPO
|
Jaspreet Grewal, MBA, MSc, CCRP• Leader in clinical medicine, research and regulatory affairs, trained in Georgetown, Yale, Harvard and LSE
|
James Topham
• BC Innovators Hall of Fame
• Former KPMG Partner, former board of BC Tech • Founder of Vancouver Social Venture Partners philanthropy group • Board member, various biotech and tech companies |